RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Clinical trials for RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat ovarian and endometrial cancers
Disease control Recruiting nowThis early-phase trial is testing the safety and best dose of two drugs, M1774 and ZEN-3694, given together to patients with recurrent ovarian or endometrial cancer. The drugs work by blocking enzymes that cancer cells need to grow. The study aims to find a dose that is safe and …
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New cocktail aims to boost immune attack on ovarian cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding an experimental immune-boosting drug (CDX-1140) to two standard immunotherapies (pembrolizumab and bevacizumab) can shrink tumors in people whose ovarian cancer has returned. About 80 adults with recurrent ovarian, fallopian tube, or perito…
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New vaccine combo shows promise in ovarian cancer fight
Disease control Recruiting nowThis study tests a new treatment for ovarian cancer that has returned after initial therapy. It combines a personalized vaccine made from a patient's own white blood cells (FRαDC) with an immunotherapy drug (pembrolizumab) to help the immune system attack cancer cells. The trial …
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC